DeCODE undertakes no obligation to update or revise these forward-looking statements as a result of new information, future events or otherwise.. The statements contained in this presentation, the future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties that could cause materially from those materially from those described in forward-looking statements. These risks and uncertainties include among other things, the provisions on technology and product development, integration of acquired businesses, market acceptance, government regulation and approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks The identified in deCODE filings with the Securities and Exchange Commission.
###About deCODEdeCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. DeCODE is a global leader in gene discovery – our population approach and resources have enabled us to key genes contributing to major public health challenges from cardiovascular diseases to isolate us with drug targets rooted in the basic biology of disease. DeCODE is also using its expertise in human genetics and integrated drug discovery and development capabilities to deliver innovative products and services in DNA diagnostics, bioinformatics, genotyping, Structural biology, drug discovery and clinical development to offer.However, surveillance a practical option to men with prostate cancer.Active surveillance has is a viable option for many men with low-risk disease, but more research is needed to determine the critical points, it should be recommended at which actively treatment of Researchers made two new studies to actively monitor when the 105 th Annual Scientific Meeting of American Urological Association in San Francisco. A particular press conference was on the 1st June 2013. The press conference will was hosted by prostate cancer expert J. Brantley Thrasher, by the University of Kansas Medical Center.
25 per cent were extracapular extension of and 7 % have seminal vesicles invaded. It are no instances of biochemical recurrence in the group. Over Detection would does not are used synonymously with overtreatment, prostate tumor can prostate cancer, Thrash said. These two studies alone show how precious an active monitoring reports can in illness being fine maintained and Recommend Excellent treatment accordingly..